VIKING THERAPEUTICS INC
NASDAQ: VKTX (Viking Therapeutics, Inc.)
Last update: yesterday, 8:31PM29.22
1.64 (5.95%)
News Mood
- 4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
- Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
AIStockmoo Score
| Value 30% | 0.0 |
| From our AI Insight report's view of expected return against risk. info | NA |
| Relative Valuation info | NA |
| Implied Growth info | NA |
| Valuation History info | NA |
| Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info | |
| Return on Capital info | NA |
| Timing 30% | -1.8 |
| From our AI technical analysis of the chart. info | NA |
| Downtrend over the past year. Far below its 52-week high. info | |
| Candle Patterns info | NA |
| Trend for Your Holding Period info | NA |
| Sentiment 20% | 0.3 |
| No recent price targets, so based on how targets have been revised. info | |
| Recent news mostly positive. info | |
| Smart Money 20% | 2.7 |
| Insider Activity info | NA |
| Institutions net +3.61% of shares in their latest 13F filings: 244 holders increased, 194 decreased (quarter to 30 Sep 2026). info | |
| Short interest +8.9% from 31 Aug to 30 Oct 2026, 5.4 days to cover (FINRA). info | |
| Market and sector conditions are poor. | |
| Market environment cautious. info | |
| Sector lagging the market. | |
| The pillars disagree, so the score is softened. | |
| Not in score | |
| Price is low against its 52-week average. Up over 5 years. info | |
| Short-term momentum rising. info | |
| Price is near resistance. info | |
| Final Score | 0.04 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Viking Therapeutics, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| VKTX | - | - | - | 6.33 |
| VRNA | 9 B | - | - | 33.01 |
| OPT | 583 M | - | - | 4.31 |
| VRCA | - | - | - | 15.60 |
| TSHA | - | - | - | 3.74 |
| ABEO | - | - | - | 1.04 |
Select this tab to load the latest available analysis.
|
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.15% |
| % Held by Institutions | 70.06% |
No data within this time range.
Institutions
Institutional ownership: 72.13%
| Positions | Holders | Shares |
|---|---|---|
| Increased | 244 | 12,854,831 |
| Decreased | 194 | 7,705,000 |
| New | 74 | 2,130,763 |
| Sold out | 67 | 2,661,975 |
SEC 13F filings via Nasdaq, latest filings up to 30 Sep 2026. Filings arrive up to 45 days after each quarter.
Short Interest
| Settlement | Shares | Days to cover |
|---|---|---|
| 30 Oct 2026 | 24,163,022 | 5.4 |
| 15 Oct 2026 | 25,538,849 | 4.4 |
| 30 Sep 2026 | 25,921,759 | 2.2 |
| 15 Sep 2026 | 22,583,758 | 12.3 |
| 31 Aug 2026 | 22,186,520 | 12.4 |
| 14 Aug 2026 | 22,285,459 | 13.3 |
FINRA short interest via Nasdaq, reported twice a month.
| Date | Type | Details |
|---|---|---|
| 13 Nov 2026 | Yahoo Finance |
4 Key Stocks to Watch Across Diabetes and Obesity This Awareness Day
LLY, NVO, VKTX and GPCR advance diabetes and obesity treatments, with promising drug candidates, expanding clinical studies and key pipeline milestones ahead. |
| 13 Nov 2026 | Yahoo Finance |
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price. |
| 12 Nov 2026 | Yahoo Finance |
Viking Therapeutics (VKTX) Heads To Two Conferences, Is The Discount To Analyst Targets Warranted?
Viking Therapeutics (VKTX) is heading into a busy stretch on the conference circuit, with back to back presentations at the Stifel 2026 Healthcare Conference and the Truist Securities BioPharma Symposium in New York next week. Recent trading tells a mixed story for Viking Therapeutics. The share… |
| 11 Nov 2026 | Yahoo Finance |
Is Viking Therapeutics (VKTX) Priced For Perfection After ObesityWeek?
Viking Therapeutics has delivered very strong long term share returns, and that kind of history can leave investors wondering whether the current US$28.44 price still lines up with what its balance sheet says the business is worth. With the spotlight on Viking Therapeutics as it pushes ahead in… |
| 11 Nov 2026 | Yahoo Finance |
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
These drugmakers offer very different risk-reward profiles. |
| 09 Nov 2026 | Yahoo Finance |
Viking Therapeutics Announces Two Poster Presentations at ObesityWeek® 2026
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will present two posters highlighting its VK2735 program at The Obesity Society's Annual… |
| 04 Nov 2026 | Yahoo Finance |
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
Viking aims to enter the weight loss drug market. |
| 03 Nov 2026 | Yahoo Finance |
Viking Therapeutics to Participate at Upcoming Investor Conferences
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Stifel 2026 Healthcare Conference, Truist 2026 BioPharma Symposium… |
| 02 Nov 2026 | Yahoo Finance |
UBS Just Initiated Coverage of Viking Therapeutics With a Buy Rating and a $94 Target. Here's the Bull Case.
Trial results for its weight loss drugs could justify a higher valuation for the clinical-stage biotech. |
| 30 Oct 2026 | Yahoo Finance |
VKTX: Is a 2029 Launch for Its Obesity Drug Within Reach?
Viking Therapeutics is set to target a potential first-half 2029 launch for VK2735, but clinical readouts, FDA review and intensifying competition could shape its timeline. |
| 30 Oct 2026 | Yahoo Finance |
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
Based on the average brokerage recommendation (ABR), Viking Therapeutics (VKTX) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying? |
| 29 Oct 2026 | Yahoo Finance |
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies. |
| 29 Oct 2026 | Yahoo Finance |
LLY Stock Jumps as Q3 Earnings Beat Estimates, 2026 Sales View Raised
Lilly's Q3 earnings and sales beat estimates, driven by Mounjaro and Zepbound, as the company raises its 2026 revenue outlook to $91-$92 billion. |
| 29 Oct 2026 | Yahoo Finance |
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases
Eli Lilly just posted a quarter that left its GLP-1 rivals in the dust, but margin pressure and a $900 million pile of one-time benefits raise questions about how much of that strength is real and how long it can last. |
| Show more | ||
Recent Signals candle patterns and EMA crosses
AI Technical Analysis
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |